Elranatamab exhibited notable signals in pancytopenia (N = 5, ROR = 6.70), pyrexia (N = 22, ROR = 5.55), chills (N = 5, ROR = 3.34), CRS (N = 70, ROR = 185.29), hypogammaglobulinemia (N = 7, ROR = 61.03), c-reactive protein increased (N = 5, ROR = 10.29), and pneumonia (N = 12, ROR = 2.90), cytomegalovirus infection reactivation (N = 3, ROR = 25.52), viral infection (N = 3, ROR = 6.28), pneumocystis jirovecii pneumonia (N = 3, ROR = 15.02), pneumonia bacterial (N = 5, ROR = 31.90) and cytomegalovirus infection (N = 10, ROR = 47.25). This evidence concerns the gene CRP and susceptibility to pneumonia measurement.